8-K: BrainStorm Reports 2025 Results, Advances ALS Trial

BrainStorm Cell Therapeutics announced its full year 2025 financial results, reporting a reduced net loss and highlighting progress on its NurOwn Phase 3b study for ALS, supported by a recent $2 million financing.

Summary

• Reported a net loss of approximately $10.3 million for the full year ended December 31, 2025, an improvement from $11.6 million in 2024.
• Net loss per share decreased to $1.11 in 2025 from $2.31 in 2024.
• Research and development expenses decreased to $4.2 million in 2025 from $4.7 million in 2024.
• General and administrative expenses decreased to $5.8 million in 2025 from $7.0 million in 2024.
• Secured $2.0 million in strategic financing through private placements in February 2026, post year-end.
• Received FDA clearance in 2025 for the planned Phase 3b confirmatory study (ENDURANCE) of NurOwn for ALS.
• The Phase 3b ENDURANCE study is designed to enroll approximately 200 participants and includes a 24-week randomized, double-blind, placebo-controlled portion (Part A) followed by a 24-week open-label extension (Part B).
• Highlighted durable long-term survival data from the Expanded Access Program (EAP) cohort, with 50% of patients (5/10) remaining alive and estimated mean survival reaching approximately 84 months.
• All 10 EAP patients exceeded 5-year survival, compared to a historical average of approximately 20%.
• Acknowledged a Citizen Petition filed with the FDA by the ALS community requesting renewed regulatory review of NurOwn data.
• Cash, cash equivalents, and restricted cash were approximately $0.3 million as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to reduced losses, significant regulatory progress for NurOwn's Phase 3b trial, and compelling EAP survival data, despite ongoing financial challenges and the need for substantial future funding.

Positives

• Net loss decreased to $10.3 million in 2025 from $11.6 million in 2024.
• Net loss per share significantly improved to $1.11 in 2025 from $2.31 in 2024.
• Research and development expenses decreased by $0.5 million to $4.2 million in 2025.
• General and administrative expenses decreased by $1.2 million to $5.8 million in 2025.
• Secured $2.0 million in strategic financing in February 2026, providing cash runway for key operational activities.
• Received FDA clearance in 2025 for the planned Phase 3b confirmatory study of NurOwn for ALS.
• Completed key regulatory steps including Special Protocol Assessment (SPA) and CMC alignment for the Phase 3b study.
• Expanded Access Program (EAP) data shows 50% of patients (5/10) remain alive with estimated mean survival of approximately 84 months.
• All 10 EAP patients exceeded 5-year survival, significantly higher than the historical ~20%.
• Focus on earlier-stage ALS populations in the Phase 3b trial, reinforced by EAP patients' higher baseline function (mean ALSFRS-R of approximately 41).
• Received a Notice of Allowance for a foundational patent covering its allogeneic exosome technology.

Negatives

• Cash, cash equivalents, and restricted cash were critically low at approximately $0.3 million as of December 31, 2025, prior to the post-year-end financing.
• Company continues to operate at a net loss of $10.3 million for the year ended December 31, 2025.
• Total assets decreased from $1,832,000 in 2024 to $1,022,000 in 2025.
• Total liabilities increased from $9,596,000 in 2024 to $11,007,000 in 2025.
• Stockholders deficit increased from $(7,764,000) in 2024 to $(9,985,000) in 2025.
• Increased accounts payables and short-term loans indicate potential liquidity pressures.

Risks

• Management's ability to successfully achieve its goals.
• BrainStorm's ability to raise additional capital.
• BrainStorm's ability to continue as a going concern.
• Prospects for future regulatory approval of NurOwn.
• Whether BrainStorm's future interactions with the FDA will have productive outcomes.
• Whether BrainStorm can successfully fund and complete the Phase 3b ENDURANCE study of NurOwn.

Future Outlook

The company's main priority is advancing NurOwn into a Phase 3b confirmatory study, having received FDA clearance in 2025. This study is designed to generate confirmatory data to support a potential Biologics License Application (BLA) submission. The company believes it has addressed primary hurdles and is positioned for success, with clinical sites on standby and active engagement with regulators. The recent $2 million financing is expected to provide cash runway for key operational activities and preparatory work for the Phase 3b trial.

Management Comments

• "Our main priority continues to be advancing NurOwn into a Phase 3b confirmatory study, having received clearance from the FDA in 2025 for the planned study."
• "This study is designed to generate confirmatory data to support a potential BLA submission."
• "Having completed key regulatory steps, the SPA, CMC alignment, and the May 2025 FDA clearance, we believe we have addressed some of the primary hurdles in our development program and positioned the company for success."
• "Our network of leading clinical sites are on standby, and we remain actively engaged with regulators."
• "Further, we believe that the $2.0 million in strategic financing secured in early 2026 has served as the catalyst for our recovery, resulting in a significant re-rating of our shares and providing the cash runway to execute on key operational activities."
• "ALS is a devastating disease with limited treatment options, and we remain committed to the ALS community as we work to complete development of NurOwn and make it available to patients."

Industry Context

StockSavvy.ai notes that BrainStorm Cell Therapeutics operates in the highly competitive and capital-intensive neurodegenerative disease space, particularly for ALS, where treatment options are limited. The progress towards a Phase 3b study for NurOwn, following FDA clearance and SPA agreement, positions the company to potentially re-enter a critical late-stage clinical phase. The emphasis on earlier-stage ALS patients for the Phase 3b trial aligns with a broader industry trend to intervene earlier in disease progression for neurodegenerative conditions, where therapeutic effects are often more pronounced. The long-term survival data from the EAP, while from a small cohort, could be a significant differentiator in a field with high unmet medical need, potentially attracting further investor and regulatory attention, especially given the Citizen Petition from the ALS community.

Comparison to Industry Standards

• The 50% survival rate (5/10 patients) and estimated mean survival of 84 months in the EAP cohort for NurOwn significantly exceed the historical 5-year survival rate of approximately 20% for ALS patients, suggesting a potentially superior outcome compared to the natural history of the disease.
• The focus on earlier-stage ALS patients (mean ALSFRS-R of approximately 41 at baseline) for the Phase 3b trial is consistent with strategies employed by other companies developing ALS treatments, such as Amylyx Pharmaceuticals (AMX0035, Relyvrio/Albrioza) and Biogen (Tofersen, Qalsody), which have also targeted specific patient populations or earlier disease stages to demonstrate efficacy.
• The $2.0 million strategic financing, while helpful for near-term operations, is relatively modest compared to the capital typically required for late-stage clinical trials in the biopharmaceutical industry, which can often run into tens or hundreds of millions of dollars. This highlights a potential funding gap for the full execution of the Phase 3b ENDURANCE study.

Stakeholder Impact

• Shareholders: The $2 million financing and progress towards Phase 3b could instill confidence, potentially leading to a "re-rating of shares" as mentioned by management. However, continued losses and the need for further capital raise risks dilution.
• ALS Patients/Community: The advancement of NurOwn to a Phase 3b study and the positive EAP survival data offer continued hope for a new treatment option. The Citizen Petition underscores the community's strong interest and advocacy.
• Employees: Continued clinical development and financing provide stability and a clear path forward for the company's mission.
• Creditors: Increased liabilities and a significant stockholders' deficit indicate ongoing financial risk, though the recent financing provides some short-term relief.

Next Steps

• Advance NurOwn into the Phase 3b confirmatory study (ENDURANCE study).
• Enroll approximately 200 participants in the Phase 3b study.
• Generate confirmatory data from the Phase 3b study to support a potential Biologics License Application (BLA) submission.
• Actively engage with regulators regarding NurOwn development.
• Utilize the $2.0 million financing for near-term operational objectives and preparatory work for the Phase 3b trial.
• Continue development of the allogeneic exosome-based platform.

Key Dates

Recommendation

While BrainStorm Cell Therapeutics has made significant progress with FDA clearance for its NurOwn Phase 3b study and reported a reduced net loss, the company remains in a high-risk, pre-revenue stage. The $2 million financing provides short-term runway but is insufficient for the full execution of a large Phase 3b trial, indicating a high likelihood of future capital raises and potential dilution. The positive EAP data is encouraging but from a small cohort. Investors should hold to monitor the progress of the Phase 3b trial and the company's ability to secure further substantial funding without excessive dilution, given the inherent uncertainties in clinical development and regulatory approval.

Keywords

BrainStorm Cell Therapeutics, BCLI, NurOwn, ALS, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Stem Cell Therapy, Phase 3b Trial, FDA Clearance, Clinical Trials, Biotechnology, Orphan Drug, Exosome Technology, Financial Results, Biopharma